## 1 Introduction
\begin{table}
\begin{tabular}{c c c c c} \hline \hline
**Site of Infection or Study Population** & **Novel Agent** & **Phase of the Clinical Trial** & **Expected Completion of the Clinical Trial (Year)** & ClinicalTrials. \\ \hline \multicolumn{5}{c}{**Indication: carbapenem-resistant _Acinetobacter baumanni_**} \\ \hline Healthy volunteers & ETX2514 and 14C-ETX2514 & Phase 1 (excretion and metabolism) & 2019 (completed) & NCT04018950 \\ \hline Healthy volunteers & ETX2514 vs. placebo vs. & Phase 1 (cardiac & 2019 (completed) & NCT03985410 \\  & moxifloxacin & repolarization) & 2018 (completed) & NCT03310463 \\ \hline Volunteers with and without renal impairment & ETX2514 plus sublactam & Phase 1 (renal safety) & 2017 (completed) & NCT02971423 \\ \hline Healthy volunteers & ETX2514 vs. ETX2514 plus & & \\ sulbactam vs. ETX2514 plus & Phase 1 (safety, tolerability and PK) & 2017 (completed) & NCT02971423 \\  & impenem/cilastatin & & \\ \hline Healthy volunteers & ETX2514 plus & 1 (plasma, epithelial & \\  & liming fluid and alveolar macrophage & 2017 (completed) & NCT03303924 \\  & concentrations) & & \\ \hline \multicolumn{5}{c}{ETX2514/sublactam + imienem/cilastin} & & \\ HABP, VABP, bacteremia & vs. & Phase 3 & 2021 (completed) & NCT03894046 \\  & colistin + imienem/cilastin & & \\ \hline Pneumonia or & \multicolumn{2}{c}{Phae treatment} & Expanded access study & 2020-not specified & NCT04636554 \\ bacteremia/septicemia & \multicolumn{2}{c}{Haged treatment} & \multicolumn{2}{c}{Expended access study} & 2020-not specified & NCT04636554 \\ \hline Diabetic foot ulcers & \multicolumn{2}{c}{Local bacteriophage therapy TP-102} & \multicolumn{2}{c}{(Local study: Israel)} & 2021-recruiting & NCT04803708 \\ \hline Critical illness with & \multicolumn{2}{c}{Polymyxin B vs.} & \multicolumn{2}{c}{Phase 3 (local study:} & \\ multi-drug resistant & \multicolumn{2}{c}{polymyxin B plus} & \multicolumn{2}{c}{Puerto Rico)} & 2019 (completed) & NCT03159078 \\ pathogens & imienem & \multicolumn{2}{c}{**Resistant Pseudomonas aeruginosa**} & \\ \hline Healthy volunteers & MEDI3902 & Phase 1 dose-escalation & \\  & MEDI3902 & study & 2018 (completed) & NCT02255760 \\ \hline Prevention of nosocomial & \multicolumn{2}{c}{} & \\ pneumonia caused by _P. aeruginosa_ in mechanically & MEDI3902 vs. placebo & Phase 2 & 2016-2020 (completed) & NCT02696902 \\ ventilated patients & & & \\ \hline \multicolumn{5}{c}{**Carbonenem-resistant Enterobacteriaceae (CRE)**} \\ \hline Colonization and clinical & \multicolumn{2}{c}{Capsulized FMT} & Local study: Israel & April 2023 & NCT04790565 \\ \hline Clinical infection with CRE & Capsulized FMT & Phase 2, 3 & June 2022 & NCT04146337 \\ \hline Colonization with CRE or & FMT with frozen stool & \multicolumn{2}{c}{Not mentioned} & March 2022 & NCT04583098 \\ \multicolumn{5}{c}{VRE} & \multicolumn{2}{c}{FMT with donor stool} & \\ VRE & samples from stool bank & Phase 2 & December 2021 & NCT03479710 \\ \hline Colonization with CRE & FMT from donors & Phase 1, 2 & February 2023 & NCT04759001 \\ \hline Colonization with CRE & Capsulized FMT & Phase 1, 2 & December 2019 & NCT03167398 \\ \hline Colonization with KPC & Capsulized FMT & Phase 2 & September 2024 & NCT04760665 \\ \hline Colonization with MDR & \multicolumn{2}{c}{FMT using allogeneic } & \multicolumn{2}{c}{FMT using allogeneic } & \\ organisms after infection, in & \multicolumn{2}{c}{human stool in glycerol} & \multicolumn{2}{c}{Phase 1} & \multicolumn{2}{c}{December 2022} & NCT02922816 \\ renal transplant recipients & \multicolumn{2}{c}{} & \\ \hline \hline \end{tabular}
\end{table} 
Table 1: Novel antimicrobials currently or recently evaluated in clinical trials.